APGE
Apogee Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Price History
Fundamentals
| Market Cap | $9.98B |
| P/E Ratio (TTM) | - |
| Forward P/E | -25.58 |
| EPS (TTM) | $-4.33 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -28.47% |
| Debt/Equity | 0.64 |
| Recommendation | Hold 2.6 |
| Analyst Target | $130.53 |
| Analysts | 12 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 88.8 |
| Beta | 0.62 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $133.16 |
| 52-Week Low | $34.34 |
| 50-Day Avg | $90.12 |
| 200-Day Avg | $72.22 |
| Avg Volume | $2.29M |
| Volume | $5.38M |
Performance Analysis
BEARISHAPGE is flashing more cautionary signals — investors should monitor closely.
Recent News
Last updated: Jun 30, 2026 21:07 UTC
Back to Screener Export Report